Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole

Study ID Alternative Stable ID Type
phs000857 Clinical Trial

Study Description

These are tumor biopsies and corresponding normal samples from patients with early stage ER+/HER2- breast cancer who had received the aromatase inhibitor letrozole for 10-21 days prior to surgery.

Archive Link Archive Accession
dbGaP phs000857

Who archives the data?

There are no publications available